Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
06 Mar 2024
06 Mar 2024
Historique:
received:
26
01
2023
accepted:
09
02
2024
revised:
01
02
2024
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
6
3
2024
Statut:
aheadofprint
Résumé
Pancreatic cancer incidence is increasing in younger populations. Differences between early onset pancreatic cancer (EOPC) and later onset pancreatic cancer (LOPC), and how these should inform management warrant exploration in the contemporary setting. A prospectively collected multi-site dataset on consecutive pancreatic adenocarcinoma patients was interrogated. Patient, tumour, treatment, and outcome data were extracted for EOPC (≤50 years old) vs LOPC (>50 years old). Of 1683 patients diagnosed between 2016 and 2022, 112 (6.7%) were EOPC. EOPC more frequently had the tail of pancreas tumours, earlier stage disease, surgical resection, and trended towards increased receipt of chemotherapy in the curative setting compared to LOPC. EOPC more frequently received 1st line chemotherapy, 2nd line chemotherapy, and chemoradiotherapy than LOPC in the palliative setting. Recurrence-free survival was improved for the tail of pancreas EOPC vs LOPC in the resected setting; overall survival was superior for EOPC compared to LOPC across the resected, locally advanced unresectable and metastatic settings. EOPC remains a small proportion of pancreatic cancer diagnoses. The more favourable outcomes in EOPC suggest these younger patients are overall deriving benefits from increased treatment in the curative setting and increased therapy in the palliative setting.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic cancer incidence is increasing in younger populations. Differences between early onset pancreatic cancer (EOPC) and later onset pancreatic cancer (LOPC), and how these should inform management warrant exploration in the contemporary setting.
METHODS
METHODS
A prospectively collected multi-site dataset on consecutive pancreatic adenocarcinoma patients was interrogated. Patient, tumour, treatment, and outcome data were extracted for EOPC (≤50 years old) vs LOPC (>50 years old).
RESULTS
RESULTS
Of 1683 patients diagnosed between 2016 and 2022, 112 (6.7%) were EOPC. EOPC more frequently had the tail of pancreas tumours, earlier stage disease, surgical resection, and trended towards increased receipt of chemotherapy in the curative setting compared to LOPC. EOPC more frequently received 1st line chemotherapy, 2nd line chemotherapy, and chemoradiotherapy than LOPC in the palliative setting. Recurrence-free survival was improved for the tail of pancreas EOPC vs LOPC in the resected setting; overall survival was superior for EOPC compared to LOPC across the resected, locally advanced unresectable and metastatic settings.
CONCLUSIONS
CONCLUSIONS
EOPC remains a small proportion of pancreatic cancer diagnoses. The more favourable outcomes in EOPC suggest these younger patients are overall deriving benefits from increased treatment in the curative setting and increased therapy in the palliative setting.
Identifiants
pubmed: 38448752
doi: 10.1038/s41416-024-02619-5
pii: 10.1038/s41416-024-02619-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clin. 2022;72:7–33.
doi: 10.3322/caac.21708
Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health. 2019;4:e137–47.
doi: 10.1016/S2468-2667(18)30267-6
pubmed: 30733056
Ward EM, Sherman RL, Henley SJ, Jemal A, Siegel DA, Feuer EJ, et al. Annual report to the nation on the status of cancer, featuring cancer in men and women age 20–49 years. JNCI: J Natl Cancer Inst. 2019;111:1279–97.
doi: 10.1093/jnci/djz106
pubmed: 31145458
pmcid: 6910179
Australian Institute of Health and Welfare. Cancer data in Australia. Canberra: AIHW; 2020.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med. 2011;364:1817–25.
doi: 10.1056/NEJMoa1011923
pubmed: 21561347
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl J Med. 2013;369:1691–703.
doi: 10.1056/NEJMoa1304369
Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111:782–94.
doi: 10.1093/jnci/djz073
pubmed: 31086963
pmcid: 6695305
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–24.
doi: 10.1016/S0140-6736(16)32409-6
pubmed: 28129987
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. New Engl J Med. 2018;379:2395–406.
doi: 10.1056/NEJMoa1809775
pubmed: 30575490
Ansari D, Althini C, Ohlsson H, Andersson R. Early-onset pancreatic cancer: a population-based study using the SEER registry. Langenbeck’s Arch Surg. 2019;404:565–71.
doi: 10.1007/s00423-019-01810-0
Tsang ES, Topham JT, Karasinska JM, Lee MKC, Williamson LM, Mendis S, et al. Delving into early-onset pancreatic ductal adenocarcinoma: how does age fit in? Clin Cancer Res. 2021;27:246–54.
doi: 10.1158/1078-0432.CCR-20-1042
pubmed: 32958704
Duffy A, Capanu M, Allen P, Kurtz R, Olson SH, Ludwig E, et al. Pancreatic adenocarcinoma in a young patient population—12-year experience at Memorial Sloan Kettering Cancer Center. J Surg Oncol. 2009;100:8–12.
doi: 10.1002/jso.21292
pubmed: 19384918
Ben-Aharon I, Elkabets M, Pelossof R, Yu KH, Iacubuzio-Donahue CA, Leach SD, et al. Genomic landscape of pancreatic adenocarcinoma in younger versus older patients: does age matter? Clin Cancer Res. 2019;25:2185–93.
doi: 10.1158/1078-0432.CCR-18-3042
pubmed: 30617137
pmcid: 6786265
Ordonez JE, Hester CA, Zhu H, Augustine M, Porembka MR, Wang SC, et al. Clinicopathologic features and outcomes of early-onset pancreatic adenocarcinoma in the United States. Ann Surg Oncol. 2020;27:1997–2006.
doi: 10.1245/s10434-019-08096-y
pubmed: 31894482
Saadat LV, Chou JF, Gonen M, Soares KC, Kingham TP, Varghese AM, et al. Treatment patterns and survival in patients with early-onset pancreatic cancer. Cancer. 2021;127:3566–78.
doi: 10.1002/cncr.33664
pubmed: 34228820
Ntala C, Debernardi S, Feakins RM, Crnogorac-Jurcevic T. Demographic, clinical, and pathological features of early onset pancreatic cancer patients. BMC Gastroenterol. 2018;18:139.
doi: 10.1186/s12876-018-0866-z
pubmed: 30208959
pmcid: 6136158
Piciucchi M, Capurso G, Valente R, Larghi A, Archibugi L, Signoretti M, et al. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology. 2015;15:151–5.
doi: 10.1016/j.pan.2015.01.013
pubmed: 25708929
BioGrid Australia. Cancer Data Collection Software: BioGrid Australia. 2020 [cited 2020 Oct 12]. Available from: https://www.biogrid.org.au/page/110/cancer-data-collection-software .
van Dam JL, Janssen QP, Besselink MG, Homs MYV, van Santvoort HC, van Tienhoven G, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140–9.
doi: 10.1016/j.ejca.2021.10.023
pubmed: 34838371
Barreto SG, Shukla PJ, Shrikhande SV. Tumors of the pancreatic body and tail. World J Oncol. 2010;1:52–65.
pubmed: 29147182
pmcid: 5649906
Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JDI, Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB. 2008;10:371–6.
doi: 10.1080/13651820802291233
pubmed: 18982154
pmcid: 2575681
Lau MK, Davila JA, Shaib YH. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas. 2010;39:458–62.
doi: 10.1097/MPA.0b013e3181bd6489
pubmed: 19924019
Tomasello G, Ghidini M, Costanzo A, Ghidini A, Russo A, Barni S, et al. Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. J Gastrointest Oncol. 2019;10:259–69.
doi: 10.21037/jgo.2018.12.08
pubmed: 31032093
pmcid: 6465486
Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402:1272–81.
doi: 10.1016/S0140-6736(23)01366-1
pubmed: 37708904
Santucci J, Tacey M, Thomson B, Michael M, Wong R, Shapiro J, et al. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: evidence from the prospective international multicentre PURPLE pancreatic cancer registry. Eur J Cancer. 2022;174:102–12.
doi: 10.1016/j.ejca.2022.06.042
pubmed: 35988408
Mendis S, Lipton L, Ananda S, Michael M, Mclachlan S-A, Thomson B, Knowles B, Fox A, Loveday B, Nikfarjam M, Usatoff V, Shapiro J, Clarke K, Pattison S, Chee CE, Zielinski R, Wong R, Gibbs P, Lee B. American Society of Clinical Oncology (ASCO) 2022 Gastrointestinal Cancers Symposium, January 20–22 2022. J Clin Oncol. 2022;40 (4_suppl):533.